[HTML][HTML] Targeting the insulin-like growth factor pathway in hepatocellular carcinoma

M Enguita-Germán, P Fortes - World journal of hepatology, 2014 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide. Only 30%-40% of the patients with HCC are eligible for curative treatments …

MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches

E Callegari, L Gramantieri, M Domenicali… - Cell Death & …, 2015 - nature.com
MicroRNAs (miRNAs) constitute a large class of short RNAs (eg, 20–24 nucleotides in
length), whose main function is to posttranscriptionally regulate the expression of protein …

Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma

M Ikeda, T Okusaka, S Mitsunaga, H Ueno… - Clinical Cancer …, 2016 - AACR
Purpose: To determine the maximum tolerable dose (MTD), safety, pharmacokinetics,
pharmacodynamics, and preliminary efficacy of lenvatinib in patients with advanced …

[HTML][HTML] Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

M Cervello, JA McCubrey, A Cusimano, N Lampiasi… - Oncotarget, 2012 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common liver cancer, accounting for 90% of
primary liver cancers. In the last decade it has become one of the most frequently occurring …

Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC

X Zhai, H Zhu, W Wang, S Zhang, Y Zhang, G Mao - Medical oncology, 2014 - Springer
We determined the expression of epithelial-mesenchymal transition (EMT) indicator
proteins, E-cadherin (E-cad), vimentin (VIM), mucin 1 (MUC1) and S100 calcium-binding …

Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy

CE Tognon, PHB Sorensen - Expert opinion on therapeutic targets, 2012 - Taylor & Francis
Introduction: The IGF system controls growth, differentiation, and development at the cellular,
organ and organismal levels. IGF1 receptor (IGF1R) signaling is dysregulated in many …

[HTML][HTML] SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting E2F1

L Chang, L Xi, Y Liu, R Liu… - Molecular medicine …, 2018 - spandidos-publications.com
Abstract Sirtuin 5 (SIRT5) is a member of the NAD+‑dependent class III protein
deacetylases. Although it is known that SIRT5 deacetylates and activates urate oxidase in …

Upregulation of FoxP4 in HCC promotes migration and invasion through regulation of EMT

G Zhang, G Zhang - Oncology letters, 2019 - spandidos-publications.com
Previous studies have indicated that FoxP1, FoxP2 and FoxP3 play important roles in
hepatocellular carcinoma (HCC). However, the effect of FoxP4 in HCC requires further …

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation

R Gedaly, P Angulo, J Hundley, MF Daily… - Journal of Surgical …, 2012 - Elsevier
BACKGROUND: Deregulated Ras/Raf/MAPK and PI3K/AKT/mTOR signaling pathways are
found in hepatocellular carcinoma (HCC). This study aimed to test the inhibitory effects of …

Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma

AR Singh, S Joshi, AM Burgoyne, JK Sicklick… - Molecular cancer …, 2016 - AACR
Abstract Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK, and c-Myc signaling pathways are of
prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug …